Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.50 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4808264 | 0.87 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4804774 | 0.83 | AKR1C1 (0.56) | AKR1C1CA12CA1CA2CA7 | |
| SCHEMBL4813835 | 0.82 | CA12 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4813998 | 0.79 | AKR1C1 (0.51) | AKR1C1CA12CA1CA2CA9 | |
| SCHEMBL20703721 | 0.78 | AKR1C1 (0.53) | AKR1C1CA12CA1CA2CA7 | |
| SCHEMBL4815384 | 0.78 | HDAC1 (0.46) | MEN1KMT2ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL23920042 | 0.77 | AKR1C1 (0.66) | AKR1C1MEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL27095683 | 0.77 | AKR1C1 (0.66) | AKR1C1MEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL23920041 | 0.76 | AKR1C1 (0.68) | AKR1C1CA12CA1CA2CA7 | |
| SCHEMBL8256047 | 0.75 | CA12 (0.56) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465719-B2 | Carbamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2008-12-16 | — | — | US | disclosed |
| US-7465719-B2 | Carbamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2008-12-16 | — | — | US | disclosed |
| US-7465719-B2 | Carbamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2008-12-16 | — | — | US | disclosed |
| US-20060058282-A1 | Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors | TOPOTARGET UK LIMITED (GB) | 2006-03-16 | — | — | US | disclosed |
| EP-1583736-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN ESTER OR KETONE LINKAGE AS HDAC INHIBITORS | TopoTarget UK Limited (GB) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004065354-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN ESTER OR KETONE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058282-A1 | Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors | HDAC1, HDAC7, HDAC11 | AKR1C1 211/4885CA12 379/4885CA1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.